1.Snakebite in Korea: A Guideline to Primary Surgical Management.
Jung Ho RHA ; Sung Min KWON ; Jin Rok OH ; Byung Keun HAN ; Kang Hyung LEE ; Jae Hyun KIM
Yonsei Medical Journal 2015;56(5):1443-1448
PURPOSE: Snakebite is an emergency which causes local symptoms such as pain and edema around the bite. Systemic symptoms may also develop, such as dizziness or renal failure, and may even cause death. The purpose of this research was to assess the validity and safety of snakebite protocol for surgery when treating snakebite patients. MATERIALS AND METHODS: Retrospective research was performed on patients who were admitted after being treated at the emergency center from January 2008 to December 2012. When necessary, debridement was also performed, and 46 of 111 patients (41.4%) underwent debridement. Those who had received debridement without antivenom administration due to a positive skin reaction test were classified as group A, and group B received antivenom and delayed debridement. We reviewed the emergency and admission charts of the patients in each group and recorded and compared their age, sex, bite site, severity of local and general symptoms, time to receive antivenin, and complications. RESULTS: Of the ten patients (21.7%) in group A, two (66.6%) developed cellulites, and one of them experienced skin necrosis, resulting in a skin graft. In group B, there were 36 patients (78.2%), 19 (52.7%) of whom developed cellulitis. Skin necrosis occurred in two patients, and one of these patients received a skin graft. Compartment syndrome was found in one patient, and fasciotomy and a skin graft were performed. CONCLUSION: The treatment protocol implemented to treat snakebite patients admitted to the emergency center during this research was safely and properly followed during surgical treatment.
Adult
;
Aged
;
Antivenins/administration & dosage
;
Combined Modality Therapy
;
Compartment Syndromes
;
Debridement/*methods
;
Disease Management
;
Edema/etiology
;
Female
;
Humans
;
Male
;
Middle Aged
;
Necrosis
;
*Practice Guidelines as Topic
;
Republic of Korea
;
Retrospective Studies
;
Severity of Illness Index
;
Skin/pathology
;
Skin Transplantation/*methods
;
Snake Bites/complications/*diagnosis/pathology/*surgery
;
Snake Venoms/adverse effects
;
Soft Tissue Injuries/etiology/*pathology/surgery
;
Treatment Outcome
;
Wound Healing/physiology
2.Selective class I histone deacetylase inhibitors suppress persistent spontaneous nociception and thermal hypersensitivity in a rat model of bee venom-induced inflammatory pain.
Fan YANG ; Yan YANG ; Yan WANG ; Fei YANG ; Chun-Li LI ; Xiao-Liang WANG ; Zhen LI ; Jun CHEN
Acta Physiologica Sinica 2015;67(5):447-454
To confirm whether class I histone deacetylase inhibitors (HDACIs) are effective in relief of peripheral inflammatory pain, the effects of two selective inhibitors, MS-275 and MGCD0103, were studied in rats inflamed by subcutaneous (s.c.) injection of bee venom (BV). The BV test is characterized by displaying both persistent spontaneous nociception (PSN) and primary hypersensitivity. Intrathecal (i.t.) pre-treatment of either MS-275 or MGCD0103 with a single dose of 60 nmol/20 μL resulted in profound suppression of both PSN and primary thermal hypersensitivity but without significant influence upon the primary mechanical hypersensitivity and mirror-image thermal hypersensitivity. Moreover, the up-regulation of both HDAC1 and HDAC2 induced by s.c. BV injection was completely suppressed by i.t. pre-treatment of MS-275. The present results provide with another new line of evidence showing involvement of epigenetic regulation of chromatin structure by HDAC1/2-mediated histone hypoacetylation in the BV-induced PSN and thermal hypersensitivity and demonstrate the beneficial effects of class I HDACIs in prevention of peripheral inflammatory pain from occurring.
Animals
;
Bee Venoms
;
administration & dosage
;
Benzamides
;
pharmacology
;
Epigenesis, Genetic
;
Histone Deacetylase 1
;
genetics
;
metabolism
;
Histone Deacetylase 2
;
genetics
;
metabolism
;
Histone Deacetylase Inhibitors
;
pharmacology
;
Hot Temperature
;
Hyperalgesia
;
drug therapy
;
Inflammation
;
drug therapy
;
Injections, Subcutaneous
;
Nociception
;
Pain
;
chemically induced
;
drug therapy
;
Pain Measurement
;
Pyridines
;
pharmacology
;
Pyrimidines
;
pharmacology
;
Rats
;
Rats, Sprague-Dawley
;
Up-Regulation
3.Effect of the combination of metformin and fenofibrate on glucose homeostasis in diabetic Goto-Kakizaki rats.
Tae Jung OH ; Ji Yon SHIN ; Gyeong Hoon KANG ; Kyong Soo PARK ; Young Min CHO
Experimental & Molecular Medicine 2013;45(7):e30-
Metformin has been reported to increase the expression of the glucagon-like peptide-1 (GLP-1) receptor in pancreatic beta cells in a peroxisome proliferator-activated receptor (PPAR)-alpha-dependent manner. We investigated whether a PPARalpha agonist, fenofibrate, exhibits an additive or synergistic effect on glucose metabolism, independent of its lipid-lowering effect, when added to metformin. Non-obese diabetic Goto-Kakizaki (GK) rats were divided into four groups and treated for 28 days with metformin, fenofibrate, metformin plus fenofibrate or vehicle. The random blood glucose levels, body weights, food intake and serum lipid profiles were not significantly different among the groups. After 4 weeks, metformin, but not fenofibrate, markedly reduced the blood glucose levels during oral glucose tolerance tests, and this effect was attenuated by adding fenofibrate. Metformin increased the expression of the GLP-1 receptor in pancreatic islets, whereas fenofibrate did not. During the intraperitoneal glucose tolerance tests with the injection of a GLP-1 analog, metformin and/or fenofibrate did not alter the insulin secretory responses. In conclusion, fenofibrate did not confer any beneficial effect on glucose homeostasis but reduced metformin's glucose-lowering activity in GK rats, thus discouraging the addition of fenofibrate to metformin to improve glycemic control.
Animals
;
Blood Glucose/metabolism
;
Body Weight/drug effects
;
Diabetes Mellitus, Experimental/*drug therapy/*metabolism
;
Drug Therapy, Combination
;
Feeding Behavior/drug effects
;
Fenofibrate/*pharmacology/therapeutic use
;
Glucagon-Like Peptide 1/agonists/metabolism
;
Glucose/*metabolism
;
Glucose Tolerance Test
;
Homeostasis/*drug effects
;
Immunohistochemistry
;
Injections, Intraperitoneal
;
Insulin-Secreting Cells/drug effects/metabolism/pathology
;
Lipid Metabolism/drug effects
;
Male
;
Metformin/*pharmacology/therapeutic use
;
Peptides/administration & dosage/pharmacology
;
Rats
;
Receptors, Glucagon/metabolism
;
Venoms/administration & dosage/pharmacology
4.In vitro anti-proliferation effect of peptides from cinobufacini injection.
Xu WU ; Bo GAO ; Jian YANG ; Bao-Lin BIAN ; Hong-Jie WANG
Acta Pharmaceutica Sinica 2012;47(6):822-826
Cinobufacini is an aqueous extract of Bufo bufo gargarizans Cantor dried skin, which has been widely used for cancer therapy in China. So far, its active components are still not very clear. In previous reports, bufadienolides with low-concentration were usually studied because of their anticancer effects. However, the high polarity constituents in cinobufacini are less investigated. The present study found that more than 50% contents of cinobufacini were water-soluble peptides. Then, in vitro anticancer experiments were carried out, including human stomach cancer cell lines BGC823 and MCG803, human colon cancer cell lines DLD-1 and HT-29, and human pancreatic cancer cell line MIAPACA-2. The IC50 for these cell lines model were ranged from 25-123 microgmL(-1). The results indicated that these peptides showed similar activity with cinobufacini injection. As a conclusion, this study provides a new and further understanding of anticancer components in cinobufacini injection.
Amphibian Venoms
;
administration & dosage
;
chemistry
;
isolation & purification
;
Animals
;
Antineoplastic Agents
;
isolation & purification
;
pharmacology
;
Bufonidae
;
Cell Line, Tumor
;
Cell Proliferation
;
drug effects
;
HT29 Cells
;
Humans
;
Injections
;
Medicine, Chinese Traditional
;
Peptides
;
isolation & purification
;
pharmacology
;
Skin
;
chemistry
5.Therapeutic potential of Naja naja atra venom in a rat model of diabetic nephropathy.
Gui Li DAI ; Jing Kang HE ; Yan XIE ; Rong HAN ; Zheng Hong QIN ; Lu Jia ZHU
Biomedical and Environmental Sciences 2012;25(6):630-638
OBJECTIVETo study the protective effects of naja naja atra venom (NNAV) in a rat model of diabetic nephropathy (DN).
METHODSThe rat diabetes model was induced by intraperitoneal injection of streptozotocin (STZ). Thirty-two model rats were randomly divided into one DN group (n=8) and three treatment groups (n=8 each) that received NNAV at doses of 30, 90, or 270 μg/(kg·day) via oral gavage, another eight rats as normal controls. After 12 weeks, all rats were sacrificed and the changes in serum and urine biological index levels were determined by colorimetric assay. Microalbumin (mALB), N-acetyl-β- glucosaminidase (NAG) and cystatin C (CysC) concentrations were measured by ELISA. Renal tissues were sliced for pathological and immunohistochemical observations.
RESULTSComparied with the DN group, serum glucose was decreased by 31.04%, total cholesterol 21.96%, triglyceride 23.78%, serum creatinine 19.83%, blood urea nitrogen 31.28%, urinary protein excretion 45.42%, mALB 10.42%, NAG 20.65%, CysC 19.57%, whereas albumin increased by 5.55%, high-density lipoprotein-cholesterol 59.09%, creatinine clearance 19.05% in the treatment group by NNAV administration at dose of 90 μg/(kg·day). NNAV also reduced the levels of malondialdehyde in serum (22.56%) and kidney tissue (9.79%), and increased superoxide dismutase concentration in serum (15%) and decreased it in renal tissue (8.85%). In addition, under light microscopy kidney structure was improved and glomerular hypertrophy decreased by 8.29%. As shown by immunohistochemistry, NNAV inhibited transforming growth factor-β1 by 6.70% and nuclear actor-κB by 5.15%.
CONCLUSIONNNAV improves biological indexes in DN, and it may exert renoprotective effects in rats with STZ-induced diabetes.
Animals ; Body Weight ; Diabetes Mellitus, Experimental ; complications ; Diabetic Nephropathies ; drug therapy ; pathology ; Dose-Response Relationship, Drug ; Elapid Venoms ; administration & dosage ; pharmacology ; Elapidae ; physiology ; Kidney ; drug effects ; pathology ; Male ; Malondialdehyde ; Organ Size ; Rats ; Rats, Wistar ; Superoxide Dismutase
6.Acute Dermal Toxicity Study of Bee Venom (Apis mellifera L.) in Rats.
Sang Mi HAN ; Gwang Gill LEE ; Kwan Kyu PARK
Toxicological Research 2012;28(2):99-102
Bee venom (Apis mellifera L. BV) has been used as a cosmetic ingredient for anti-ageing, anti-inflammatory and antibacterial functions. The aim of this study was to evaluate the acute toxicity after a single dermal administration of BV, BV was administered to 2 groups of Sprague-Dawley (SD) male and female rats (5 animals/group) at doses of 0 and 1,500 mg/kg body weight (BW). Mortality, clinical signs, body weight changes and gross findings were continually monitored for 15 days following the single dose. There were no unscheduled deaths in any groups during the study period. No BV related clinical signs and body weight changes were observed in any groups during the study period. There were no abnormal gross findings at necropsy on day 15 after the treatment. On the basis of the above results, it was concluded that there were no treatment-related effect on mortality, clinical signs, body weight changes and gross findings in SD rats treated with a single dermal dose of BV at dose of 1,500 mg/kg BW. Therefore, the approximate lethal dose of BV was considered to be over 1,500 mg/kg/day for both sexes of rats. BV may provide a developmental basis for a cosmetic ingredient or external application for topical uses.
Administration, Cutaneous
;
Animals
;
Bee Venoms
;
Bees
;
Body Weight
;
Body Weight Changes
;
Cosmetics
;
Female
;
Humans
;
Male
;
Rats
7.Preventive effects of jiedu granules combined with cinobufacini injection versus transcatheter arterial chemoembolization in post-surgical patients with hepatocellular carcinoma: a case-control trial.
Zhe CHEN ; Hong-yun CHEN ; Qing-bo LANG ; Bai LI ; Xiao-feng ZHAI ; Yu-yu GUO ; Xiao-qiang YUE ; Chang-quan LING
Chinese journal of integrative medicine 2012;18(5):339-344
OBJECTIVETo investigate the therapeutic effects of Jiedu granules, a Chinese medicine (CM) compound, plus cinobufacini injection, which was extracted from skin of Bufo bufo gargarizans Cantor, to prevent the recurrence of hepatocellular carcinoma (HCC) after surgical resection.
METHODSIn this case-control trial, a total of 120 patients who stayed in Changhai Hospital were enrolled from December 2001 to December 2006. Sixty patients were treated with Jiedu granules plus cinobufacini injection to prevent tumor recurrence after operation (CM group) and 60 patients were treated with transcatheter arterial chemoembolization (TACE) after operation (TACE group). Progression-free survival (PFS) and overall survival (OS) rates were determined to evaluate the therapeutic effects of post-operative management of patients with HCC.
RESULTSPFS in the CM group was 18.07 months [95% confidence interval (CI): 12.49-23.65] and the 1-, 2-, 3-, 4- and 5-year PFS rates were 61%, 39%, 26%, 22% and 12%, respectively. PFS in the TACE group was 8.03 months (95% CI: 6.63-9.44) and the 1-, 2-, 3-, 4- and 5-year PFS rates were 34%, 11%, 7%, 2% and 0%, respectively. There was significant difference in survival rate between the two groups (P<0.01). The mean survival time (MST) of patients in the CM group was 49.53 months versus 39.90 months of the TACE group. The 1-, 2-, 3-, 4- and 5-year survival rates were 90%, 82%, 80%, 70% and 63%, respectively, in the CM group, and 79%, 70%, 60%, 60% and 36%, respectively, in the TACE group. There was significant difference in survival time between the two groups (P=0.045).
CONCLUSIONSJiedu granules plus cinobufacini injection, a combination that is commonly used for post-operation management of HCC, can postpone tumor recurrence and metastasis, prolong the survival time and increase the survival rate of post-surgical patients with HCC. However, these findings need to be confirmed in a prospective, randomized controlled trial.
Adolescent ; Adult ; Aged ; Aged, 80 and over ; Amphibian Venoms ; administration & dosage ; Carcinoma, Hepatocellular ; drug therapy ; mortality ; surgery ; Case-Control Studies ; Chemoembolization, Therapeutic ; methods ; Combined Modality Therapy ; Drug Therapy, Combination ; Drugs, Chinese Herbal ; administration & dosage ; Female ; Humans ; Injections, Intra-Arterial ; Liver Neoplasms ; drug therapy ; mortality ; surgery ; Male ; Middle Aged ; Neoplasm Recurrence, Local ; prevention & control ; Retrospective Studies ; Young Adult
8.Inhibitory effect of total bufadienolides from toad venom against H22 tumor in mice and their metabolites.
Zongyun LI ; Huimin GAO ; Jinhua WANG ; Ting QU ; Liangmian CHEN ; Zhimin WANG ; Qiwei ZHANG
China Journal of Chinese Materia Medica 2011;36(21):2987-2993
OBJECTIVETo evaluate the inhibitory effect of total bufadienolides from toad venom against H22 tumor in mice and preliminarily analyze the structures of the metabolites in tissues.
METHODHPLC and LC-MS were used for analysis of the chemical composition of TBFs. High, middle and low dosages of TBFs were orally administered or intra-peritoneally injected to H22 tumor-bearing mice for thirteen days. The animals were killed and the tumors were stripped and weighed. The metabolites in the tissues such as heart, liver, spleen, lung and kidney, were analyzed by HPLC and LC-MS.
RESULTThe chemical composition of TBFs were identified by comparison of the retention times with those of reference substances, on-line UV spectra and MS data. Its main components are concerned with gamabufotalin, arenobufagin, bufotalin, resibufagin, cinobufotalin, bufalin, cinobufagin and resibufogenin. TBFs had no obvious influence on body weight of H-22 tumor-bearing mice orally administered and the inhibition rate against tumor were 14.76%, 16.38% and 10.32% for low (5 mg x kg(-1)), middle (10 mg x kg(-1)) and high dosage (20 mg x kg(-1)), respectively. The mice intra-peritoneally injected with middle and high-dose of TBFs gained body weight slower than the control mice on the 5th day and recovered on the 13th day. The inhibition rate against tumor were 17.30%, 19.80% and 40.95% for low (1.5 mg x kg(-1)), middle (3 mg x kg(-1)) and high dose (6 mg x kg(-1)), respectively. The inhibitory effect took on dose-dependent manner. Based on the HPLC analyses on heart, liver, spleen, lung and kidney, bufadienolides were found in the liver tissue and 11 compounds of them were tentatively identified by LC-DAD-MS.
CONCLUSIONTBFs by oral administration had no inhibitory effect against H22 tumor in mice, however, TBFs by intra-peritoneal injection displayed the significantly inhibitory effect, accompanying some toxicity for early duration of the study. The identification of bufadienolides in the liver provides a good basis for the further investigation of the metabolic pathways of TBFs in vivo.
Amphibian Venoms ; chemistry ; Animals ; Antineoplastic Agents, Phytogenic ; administration & dosage ; metabolism ; Bufanolides ; administration & dosage ; metabolism ; Carcinoma, Hepatocellular ; drug therapy ; metabolism ; physiopathology ; Cell Line, Tumor ; Cell Proliferation ; drug effects ; Drug Administration Routes ; Female ; Humans ; Male ; Mice ; Mice, Inbred ICR ; Neoplasm Transplantation
9.Foreign Body Granuloma Following Dried Honey Bee Venom (Apitoxin Inj) Injection.
Jong Sun LEE ; Yong Sun CHO ; Ki Hun SONG ; Su Ran HWANG ; Jin PARK ; Seok Kweon YUN ; Han Uk KIM
Korean Journal of Dermatology 2011;49(10):943-947
Bee sting therapy is sometimes used for the treatment of chronic recalcitrant neuralgia and arthralgia in traditional Korean herbal medicine, but retained sting materials at the treatment site may induce granulomatous inflammation. Recently, dried honey bee venom (Apitoxin Inj, Guju Pharma. Co., Seoul, Korea) has been approved by the Korea Food and Drug Administration (KFDA) as an anti-inflammatory drug. The adverse events associated with dried honey bee venom injection include itching, edema, pain, headache, fever and myalgia, but foreign body granuloma caused by drug injection has not been previously reported. We herein report two interesting cases of foreign body granuloma induced by dried honey bee venom injection.
Arthralgia
;
Bee Venoms
;
Bees
;
Bites and Stings
;
Edema
;
Fever
;
Foreign Bodies
;
Granuloma, Foreign-Body
;
Headache
;
Herbal Medicine
;
Honey
;
Inflammation
;
Korea
;
Neuralgia
;
Pruritus
;
United States Food and Drug Administration
10.Effect of polypeptide extract from scorpion venom (PESV) on immune escape of Lewis lung carcinomas.
Lin XU ; Weidong ZHANG ; Zhaopeng WANG ; Qing JIA ; Yueying ZHANG ; Guosheng JIANG
China Journal of Chinese Materia Medica 2010;35(17):2324-2327
OBJECTIVETo study the effects of polypeptide extract from scorpion venom (PESV) on immune escape of Lewis lung carcinomas (LLC) and its mechanism.
METHODForty C57BL/6J mice were inoculated with LLC cells suspension (1 x 10(7) cells/ mL) in right armpit subcutaneously. The tumor-bearing mice were randomly divided into two groups: the control group and the PESV group. PESV was intragastrically subjected to the mice of the experimental group for 18 days. The tumor volume and tumor inhibitory rate were determined. The expression levels of VEGF,TGF-beta1 and IL-10 in tumor microenvironment were determined by immunohisto-chemistry-staining and ELISA. Surface co-stimulatory molecules CD80 and CD86 of tumor infiltrating dendritic cells (DC) were determined by immunohistochemistry-staining and flow cytometry.
RESULTThe growth inhibitory rate of PESV was 56. 60%. The expression levels of VEGF,TGF-beta1 and IL-10 were decreased in tumor and serum, while the expression of co-stimulatory molecules CD80 and CD86 on DC were increased in tumor. Compared with the control group, the differences were all significant (P < 6.05).
CONCLUSIONPESV was effective in recovering immuno-surveillance and intervening immune escape of lung cancer through multi-pathway. And its effects might be attained by decreasing the level of VEGF, TGF-beta1 and IL-10 in tumor microenvironment and increasing the expression of co-stimulatory molecules CD80 and CD86 on DC.
Animals ; B7-1 Antigen ; immunology ; B7-2 Antigen ; immunology ; Carcinoma, Lewis Lung ; drug therapy ; immunology ; Disease Models, Animal ; Humans ; Interleukin-10 ; immunology ; Lung Neoplasms ; drug therapy ; immunology ; Male ; Mice ; Mice, Inbred C57BL ; Peptides ; administration & dosage ; immunology ; isolation & purification ; Scorpion Venoms ; chemistry ; immunology ; Tumor Escape ; drug effects

Result Analysis
Print
Save
E-mail